SCHEMBL16670299

SCHEMBL16670299

COc1ccc(N(C)C(=O)C(Cc2ccccc2)NC(=O)NS(=O)(=O)c2ccccc2C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.47
MMP2 P08253 3/20 0.46
MMP9 P14780 3/20 0.46
MMP1 P03956 1/20 0.46
MMP8 P22894 1/20 0.46
BMP1 P13497 2/20 0.45
KMT2A Q03164 1/20 0.45
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
POLB P06746 1/20 0.41
ALDH1A1 P00352 1/20 0.41
ALOX15 P16050 1/20 0.41
PYGL P06737 1/20 0.41
KEAP1 Q14145 1/20 0.41
USP30 Q70CQ3 1/20 0.41
ATM Q13315 2/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
GAA P10253 1/20 0.40
PPARG P37231 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16670298 1.00 FPR2 (0.47) FPR2MMP2MMP9MMP1MMP8
SCHEMBL16670470 0.93 MMP2 (0.42) FPR2MMP2MMP9MMP1MMP8
SCHEMBL16670467 0.93 MMP2 (0.42) FPR2MMP2MMP9MMP1MMP8
SCHEMBL16669943 0.91 MMP9 (0.51) MMP2MMP9MMP1MMP8KDM1A
SCHEMBL16669942 0.91 MMP9 (0.51) MMP2MMP9MMP1MMP8KDM1A
SCHEMBL16669642 0.91 MMP1 (0.45) FPR2MMP2MMP9MMP1MMP8
SCHEMBL16681985 0.91 GAA (0.46) MMP2MMP9MMP1MMP8KMT2A
SCHEMBL18041029 0.91 GAA (0.46) MMP2MMP9MMP1MMP8KMT2A
SCHEMBL16669644 0.91 MMP1 (0.45) FPR2MMP2MMP9MMP1MMP8
SCHEMBL16670607 0.90 MMP1 (0.42) MMP2MMP9MMP1MMP8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2016-09-08 US disclosed
EP-3060554-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2016-08-31 EP disclosed
WO-2015061518-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR1E, POLR1G FPR2 4162/4885MMP2 1544/4885MMP9 2601/4885
US-10035760-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR1G, POLR1E FPR2 4096/4885MMP2 1711/4885MMP9 2622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.